tbuckley/cabot-search huggingface dataset:
Abstract 2104: Molecular alterations in JAK1 and JAK2 genes in head and neck squamous cell carcinoma
Authors: Thaís G. Carvalho, André Lopes Carvalho, André Luiz Vettore
Journal: Cancer Research (2012)

Abstract Among the ten most common cancers are the head and neck tumors, with more than 600,000 new cases diagnosed annually worldwide, the majority (90%) represented by the head and neck squamous cell carcinomas (HNSCC). Somatic mutations occur in the genomes of all dividing cells, both normal and neoplastic. The JAK-STAT signaling pathway controls important cell events such as survival, proliferation and differentiation. The presence of mutations in the phosphorylation dominion of protein kinases as JAK family have been linked to development of different kinds of tumors such as hematological, breast, lung and gastric cancers. Furthermore, inhibitors of protein kinases (Gefitinib and Erlotinib) have demonstrated a remarkable efficacy in treatment of some cancers. To date, we do not succeeded in finding reports linking mutations in members of the JAK-STAT pathway and HNSCC. Therefore it is necessary to plunge into molecular research that could identify failures in the cellular machinery with consequent discovery of potential molecular targets and drug direct delivered to them. The present work aims to evaluate the presence of mutations in the JAK-STAT signaling pathway members (JAK1 and JAK2) and verify the expression level of these genes in HNSCC samples. For the mutation detection, primers were designed to cDNA molecules and allowed the amplification of contiguous 700-bp fragments that cover the entire coding region of each gene. The JAK1 and JAK2 genes were investigated in 20 HNSCC samples and no mutation was detected. Polymorphisms were found in JAK1 at codons 193 (20%), 659 (5%), 683 (25%), 699 (10%), 733 (25%) and 1032 (20%) and in JAK2 codons 163 (60%), 830 (85%) and 1063 (5%). In addition we evaluated the expression level of these genes in 87 HNSCC samples and both were found downreguted in the majority of HNSCC samples (JAK1 in 82% and JAK2 in 81%). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2104. doi:1538-7445.AM2012-2104
Accumulation of Tc-99m Tetrofosmin in Multiple Myeloma
Authors: TATSURO KAMINAGA, KOUICHI TAKADA, KIMIKO KUTOMI, ERIKA IMAI
Journal: Clinical Nuclear Medicine (2002)

KAMINAGA, TATSURO M.D.; TAKADA, KOUICHI M.D.; KUTOMI, KIMIKO M.D.; IMAI, ERIKA M.D. Author Information
EFECTIVIDAD DEL DRENAJE DE ABSCESOS PÉLVICOS GUIADO POR ECOENDOSCOPIA
Authors: I Fernández-Urién, JJ Vila, F Bolado, J Urman, FJ Jiménez
Journal: Endoscopy (2011)

Introducción: La ecoendoscopia permite el tratamiento de colecciones y abscesos pélvicos de una forma poco invasiva aunque las series publicadas recogen un volumen muy escaso de pacientes.
SP0099 A Comorbid SjÖGren Patient: Which Organ Has Priority?
Authors: M. Al Suwaidi
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> Primary Sjögren9s syndrome (pSS) is a systemic autoimmune disorder that predominantly affects exocrine glands leading to eye and mouth dryness, fatigue and pain. However, up to 40% of the affected patients will develop extraglandular involvement during the disease course attributed to lymphocytic infiltration of affected organs including the lungs, kidneys and liver. In addition, immune complex mediated manifestations might occur as purpura, peripheral neuropathy or glomerulonephritis. It is not uncommon for this disease entity to present itself as a diagnostic dilemma and to pose therapeutic challenges especially in cases of multiple organ involvement. To underline the complexity of this condition, we will present two difficult cases outlining the disease course right from the initial presentation and ending with the most recent clinical status. This will be followed by a detailed discussion pertaining to the diagnostic and therapeutic challenges as well as the respective complications that may arise. The first case involves a 78 year old female patient, who developed severe pulmonary involvement in the form of nonspecific interstitial pneumonia (NSIP) and pulmonary hypertension. The second case presentation will focus on a 71 year old female patient developing severe neurological manifestations with progressive polyneuropathy leading to tetraparesis of the extremities. Both cases should raise awareness to the wide array of clinical presentations, their ambiguity especially in the lack of histological evidence, the sequelae that follow and last but not least, the degree of associated morbidity not only related to the pathophysiology of this condition but also to that resulting from immunosuppressive therapy. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6191
GENERATION OF NITINOL STENT ASSOCIATED WITH REINTERVENTION OR REOCCLUSION AT 1 YEAR AFTER FEMOROPOPLITEAL NITINOL STENTING.
Authors: Takehiro Homma, Osami Kawarada, Shingo Sakamoto, Koichiro Harada, Teruo Noguchi, Satoshi Yasuda, Hisao Ogawa
Journal: Journal of the American College of Cardiology (2015)
ADDITIVE VALUE OF QUANTITATIVE PERFUSION PARAMETERS OF CARDIAC POSITRON EMISSION TOMOGRAPHY IN THE DETECTION OF FUNCTIONALLY SIGNIFICANT CORONARY STENOSIS
Authors: Chee Hae Kim, Bon Kwon Koo, Ji-Hyun Jung, Eun-Seok Shin, Minseok Suh, Gi Jeong Cheon, Jin Chul Paeng, Jung-kyu Han, Han-Mo Yang, Kyung Woo Park, Dong-Ju Choi, Hyo-Soo Kim, Byung-Hee Oh, Young-Bae Park
Journal: Journal of the American College of Cardiology (2015)
A New Hemoglobin Variant with Sickling Properties
Authors: Lawrence E. Pierce, Charles E. Rath, Kenneth McCoy
Journal: New England Journal of Medicine (1963)

THE red-cell sickling tendency of certain persons has long been a matter of great interest. Study of this problem by Pauling and his associates1 led to the suggestion of a genetic change in hemoglobin formation that resulted in synthesis of different globin fractions for normal and sickle-cell hemoglobin. Subsequent investigation by Ingram2 has shown the specific globin abnormality to be a single amino acid substitution, valine for glutamic acid, in each identical half hemoglobin molecule containing approximately 300 amino acids. Sickle-cell anemia thus became the first example of a molecular disease in which the product of gene mutation was characterized . . .
¿ES EL BALÓN INTRAGÁSTRICO SEGURO EN EL TRATAMIENTO DE LA OBESIDAD?
Authors: A Diaz Perez, M Mieses Pun, M Bautista, M Rivero, B Castro Senosiain, J De la Peña García
Journal: Endoscopy (2012)

Introducción: El balón intragástrico (BIG) constituye un tratamiento de la obesidad más eficaz que los métodos conservadores y con menos riesgo que la cirugía aunque existe una falta de consenso sobre sus indicaciones y limitaciones. Objetivos: Revisar las indicaciones y resultados de los BIG colocados en nuestro centro (hospital de tercer nivel) en el último periodo de 9 años. Material y método: se identificaron 46 pacientes a los que se les había colocado BIG (enero 2003-diciembre 2011). Se elaboró una base de datos que recogía las características epidemiológicas de los pacientes, la indicación, las complicaciones durante el tratamiento y los resultados tras la retirada del BIG. Resultados: Se colocaron BIG a un total de 46 pacientes con una mediana de edad de 50 años (18–68 años) de predominio femenino 32/14, siendo el valor medio del peso e IMC al momento de la colocación de 123.44Kg (68–170) y 44.99Kg./m2 (33.3–76), respectivamente. El 67% de los pacientes presentaban una o varias comorbilidades (HTA, diabetes, enfermedad pulmonar o cardiaca). La indicación para la colocación del BIG más frecuente fue el fracaso del tratamiento dietético (14 pacientes), seguido por tratamiento previo a la cirugía (13) y contraindicación para la cirugía bariátrica (6). Aparecieron complicaciones tras la colocación del BIG en el 27% de los pacientes siendo la mas frecuente vómitos incoercibles y/o esofagitis péptica (7 casos). La tasa global de retirada precoz del BIG se situó en el 22,73% siendo por indicación médica ante las complicaciones en el 63% de los casos. En los 36 pacientes que cumplieron con el tiempo de estancia indicado para el BIG (5–8 meses), la media de pérdida de peso fue de 13,51Kg y de IMC 3,09Kg/m2. Conclusiones: En nuestra experiencia el BIG, constituye un procedimiento eficaz y seguro para el tratamiento temporal de la obesidad mórbida, siendo su principal inconveniente la aparición de complicaciones que en nuestra cohorte dio lugar a la retirada precoz del mismo en mas de uno de cada 5 pacientes.
Abstract P4-09-09: Serum SDF-1: Biomarker of Bone Relapse in the NCIC MA.14 Adjuvant Breast Cancer Trial
Authors: SM Ali, A Aguilar-Mahecha, J-AW Chapman, A Lipton, K Leitzel, K Jahan, S Hassan, LE Shepherd, L Han, CF Wilson, KI Pritchard, MN Pollak, M. Basik
Journal: Cancer Research (2010)

Abstract Background: Massague et al have shown that breast cancer cell line subpopulations with elevated bone metastatic activity overexpress chemokine receptor 4 (CXCR4), interleukin 11 (IL11), osteopontin (OPN) and connective tissue growth factor (CTGF) (Cancer Cell 3:537, 2003). CXCR4 overexpression results in bone-homing and extravasation of tumor cells in bone. In MA.14, we found that serum β-CTx was associated with bone-only relapse while Basik et.al showed that higher serum stromal cell-derived factor 1 (SDF-1) (ligand for CXCR-4) levels were associated with worse overall event-free survival (EFS) (ASCO 2010). In this study, we examined concurrently the association of both β-CTx and serum SDF-1 with bone relapse. Methods: Serum β-CTx (Serum CrossLaps, Nordic Biosciences, Copenhagen, DN) was determined in pretreatment sera from 621 of 667 NCIC CTG MA.14 patients. SDF-1 (CXCL12) (R&amp;D Systems, Minneapolis, MN) levels were successfully determined in the 4 month post-treatment serum (SDF-1) for 508 (76%) of the patients. Trial stratification was by administration of adjuvant chemotherapy, axillary lymph node status, and ER and/or PR status. Recurrence-free survival (RFS) was defined as the time from randomization to the time of recurrence of the primary disease. Adjusted and unadjusted Cox step-wise forward multivariate analyses were used to assess the effects of β-CTx, SDF-1, trial therapy and baseline patient characteristics on non-bone, all bone and bone-only RFS; a factor was added if p&amp;lt;=0.05. Results: Joint assessment of β-CTx and SDF-1 was possible for 493 (74%) of the 667 patients. Imbalances in who was, or was not, included in this subset led to the trial arm of Tamoxifen + Octreotide LAR having a significant longer unadjusted ITT non-bone RFS (p=0.03-0.06). There was shorter time to bone metastasis of any type with higher lymph node involvement (p=0.001), larger T (p=0.02), and higher log SDF-1 (p=0.03). Meanwhile, high categorical and continuous β-CTx was associated multivariately with shorter bone-only RFS (p=0.04 and 0.01, respectively); higher log SDF-1 was only associated with shorter bone-only RFS (p=0.02) when the number of strata were reduced to 2 categories per factor. Conclusions: Higher serum SDF-1 level may be associated with bone metastasis, although there is less evidence of its relevance in bone-only relapse than there is for the biomarker β-CTx. Serum SDF-1 deserves further study as a promising predictive factor of bone relapse in breast cancer. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-09-09.
A Controlled Trial of Itraconazole to Prevent Relapse of<i>Penicillium marneffei</i>Infection in Patients Infected with the Human Immunodeficiency Virus
Authors: Khuanchai Supparatpinyo, Joseph Perriens, Kenrad E. Nelson, Thira Sirisanthana
Journal: New England Journal of Medicine (1998)

In Southeast Asia, disseminated infection with Penicillium marneffei is common among patients with human immunodeficiency virus (HIV) infection. Even after successful primary treatment, the relapse rate for this potentially fatal systemic fungal infection is about 50 percent.
1329 DIAGNOSTIC ACCURACY OF A NEW ELASTOGRAPHIC METHOD (SHEAR WAVE™ ELASTOGRAPHY IMAGING) IN THE NONINVASIVE ASSESSMENT OF NON-ALCOHOLIC STEATOSIS IN PATIENTS WITH TYPE 2 DIABETES
Authors: O.V. Virchenko, P. Bodnar, O.B. Dynnyk, G. Mykhalchyshyn, N. Kobyliak
Journal: Journal of Hepatology (2013)
Comparison of Regularly Scheduled with As-Needed Use of Albuterol in Mild Asthma
Authors: Jeffrey M. Drazen, Elliot Israel, Homer A. Boushey, Vernon M. Chinchilli, John V. Fahy, James E. Fish, Stephen C. Lazarus, Robert F. Lemanske, Richard J. Martin, Stephen P. Peters, Christine Sorkness, Stanley J. Szefler
Journal: New England Journal of Medicine (1996)

Inhaled beta-agonists are the most commonly used treatment for asthma, but data suggest that regularly scheduled use of these agents may have deleterious effect on the control of asthma. We compared the effects of regularly scheduled use of inhaled albuterol with those of albuterol used only as needed in patients with mild chronic, stable asthma.In a multicenter, double-blind study, we randomly assigned 255 patients with mild asthma to inhale albuterol either on a regular schedule (126 patients) or only as needed (129 patients). The patients were followed for 16 weeks.The primary outcome indicator, peak expiratory air flow measured in the morning, did not change significantly during the treatment period in the scheduled (416 liters per minute after the run-in period and 414 liters per minute after the treatment period) or the as-needed (424 liters per minute at both times) treatment groups (P=0.71). There were no significant differences between the two groups in peak flow variability, forced expiratory volume in one second, the number of puffs of supplemental albuterol needed, asthma symptoms, asthma quality-of-life score, or airway responsiveness to methacholine. The statistically significant differences between the groups in evening peak flow and in the short-term bronchodilator response to inhaled albuterol were small and judged to be clinically unimportant.In patients with mild asthma, neither deleterious nor beneficial effects derived from the regular use of inhaled albuterol beyond those derived from use of the drug as needed. Inhaled albuterol should be prescribed for patients with mild asthma on an as-needed basis.
AB0152 Low avidity anti-citrullinated protein antibodies (ACPA) are associated with enhanced radiological progression in rheumatoid arthritis
Authors: A. Willemze, P. Suwannalai, K. Britsemmer, R. Knevel, H. Scherer, E. Levarht, A. van der Helm-van Mil, D. van Schaardenburg, T. Huizinga, R. Toes, L. Trouw
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> Anti-citrullinated protein antibodies (ACPA) are specific for Rheumatoid Arthritis (RA) and have been implicated in disease pathogenesis. Previously we have shown that ACPA display a considerably lower avidity as compared to antibodies against recall antigens. Nonetheless, ACPA-avidity did vary between patients. As antibody-mediated effects are influenced by antibody-avidity, we now investigated ACPA-avidity in relation to biological activity and clinical outcome. <h3>Methods</h3> We determined the avidity of ACPA and related this with severity of joint damage in two Dutch early-RA cohorts containing 199 and 132 patients respectively. Differences in effector functions of low and high avidity ACPA were studied. <h3>Results</h3> Extensive variation in ACPA avidity between patients was observed. This allowed the analysis of the relationship between avidity and severity. The presence of low avidity ACPA is associated with a higher rate of joint destruction. This finding was replicated in an independent cohort. Analysis of the properties of low-versus high avidity ACPA revealed that low avidity ACPA are less hampered in their ability to bind “new” citrullinated antigens. Although no differences could be observed regarding cellular activation via Fc-gamma receptors, low avidity ACPA were more potent in activating the complement system. <h3>Conclusions</h3> Patients with low avidity ACPA display a higher rate of joint destruction. Low avidity ACPA display a higher potency to interact with more citrullinated antigens in time and show that low avidity ACPA are more potent in complement activation. These data indicate that (low) avidity impacts on the biological activity of ACPA and associates with worse radiological outcome. <h3>Disclosure of Interest</h3> None Declared
AB0167 Effects of early diagnosis on disease activity and functional disability in rheumatoid arthritis
Authors: D. Kim, C.-B. Choi, Y.-K. Sung, S.-K. Cho, S.-Y. Park, J.-Y. Choi, D.-H. Yoo, S.-S. Lee, J. Lee, J. Kim, H.-S. Lee, T.-H. Kim, B. Y. Yoon, W.-H. Yoo, J.-Y. Choe, S.-H. Lee, S.-C. Shim, W. T. Chung, S.-J. Hong, C. K. Lee, E. Koh, J.-B. Jun, S.-Y. Bang, S.-K. Kim, H.-S. Cha, L. Lee
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Early and aggressive treatment offers better outcomes in early rheumatoid arthritis (RA). The long-term effect of early treatment and effect of early treatment on functional disability have not been studied. <h3>Objectives</h3> To determine whether early diagnosis and treatment have long-term benefits for disease activity and functional disability in patients with RA enrolled in the KORean Observational study Network for Arthritis (KORONA). <h3>Methods</h3> A total of 4540 rheumatoid arthritis patients completed questionnaires to establish their demographic profile, medical history, disease-specific outcomes, and RA-related information. We defined early and delayed RA diagnoses as lag-times of shorter than and at least 1 year. Disease activity was measured with the DAS28–ESR, and it was dichotomized using a score of 2.6. Functional disability was measured with the Korean HAQ-DI, and was dichotomized using a score of 1. We used the chi-square test and <i>t</i>-test to identify differences between male and female patients, and crude and multiadjusted models to identify the impacts of early diagnosis on disease activity and functional disability. <h3>Results</h3> In crude and multiadjusted models, early diagnosis was not associated with a higher remission rate (OR 1.10, CI 0.94-1.28 in crude model, OR 1.05, CI 0.83-1.32 in multiadjusted model). We performed subgroup analysis according to disease duration; there was no association between early diagnosis and remission rate. Early diagnosis was associated with functional disability in crude model (OR 0.79, CI 0.68-0.91) but not in multiadjusted model (OR 0.85, CI 0.72-1.002). In subgroup analysis according to disease duration and disease activity, early diagnosis was independently associated with functional disability for a shorter disease duration (OR 0.78, CI 0.63-0.96 in disease duration &lt;10 years) and the presence of moderate-to-severe disease activity (OR 0.83, CI 0.69-0.99 in DAS28-ESR ≥3.2). <h3>Image/graph</h3> <h3>Conclusions</h3> Early diagnosis is associated with functional disability especially with a disease duration of less than 10 years and the presence of moderate-to-severe disease activity. <h3>Disclosure of Interest</h3> None Declared
PWE-144 Endoscopic ultrasound in the evaluation of liver hilar pathology
Authors: S Putta, D Croagh, R Boulton, S Brahmall, C Forde, B Mahon
Journal: Gut (2012)

<h3>Introduction</h3> Liver hilar pathology has traditionally been challenging to investigate as histological diagnosis is often difficult to obtain. The diagnostic yield of existing techniques including ERCP is suboptimal. Patients have consequently been managed in the absence of histological diagnosis, with the attendant hazards, including potential metal stent placement or unwarranted surgery in the absence of malignant disease. Upto 15% of patients with suspected biliary malignancy who undergo surgery are found to have benign disease. The utility of endoscopic ultrasound has not been established and our study aims to evaluate the role of EUS in this setting. <h3>Methods</h3> This is a retrospective review of all patients with a hepatic hilar stricture and or mass, who were reviewed at the hepatobiliary multidisciplinary meeting between July 2006 and September 2011 and went on to have an EUS examination. Patients with presumed benign disease were followed until they underwent definitive surgery, or for 1-year with serial cross sectional imaging. <h3>Results</h3> 95 patients with hilar lesions underwent 114 EUS examinations. 67 (70%) patients were diagnosed to have malignant disease. 58 patients had biliary tarct cancer. EUS-FNA yielded a positive cytological diagnosis in 52 (78%) patients. In 15 patients EUS cytology was false negative. 28 patients were diagnosed with benign disease. Factors that predicted malignant disease at EUS examination included the presence of a bile duct associated mass lesion (p value 0.0001) and an EUS morphological diagnosis of cancer (p value 0.03). The presence of "pathological" lymph nodes was not statistically significant (p value 0.79). Sensitivity in obtaining a cytological diagnosis, accuracy in defining benign and malignant disease, specificity and negative predictive value of EUS were 78%, 85%, 100%, and 66% respectively. Metal stent insertion was contemplated in atleast two patients following cross sectional imaging but was abandoned after EUS confirmed the benign nature of their condition. <h3>Conclusion</h3> In the largest series to date we report high sensitivity (80%) for EUS cytology in the diagnosis of malignant disease and accuracy (85%) in distinguishing malignant from benign disease. EUS had a significant impact on the clinical management of our patients, including prevention of potential metal stent placement in atleast two patients who were eventually diagnosed with benign disease. <h3>Competing interests</h3> None declared. <h3>Reference</h3> 1. <b>Fritscher-Ravens A</b>, Broering DC, Knoefel WT, <i>et al.</i> EUS-guided FNA of suspected hilar cholangiocarcinoma in potentially operable patients with negative brush cytology. <i>Am J Gastroenterol</i> 2004;<b>99</b>:45–51.